Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …

Atherothrombotic complications are the main cause of mortality in subjects with diabetes.
Premature atherosclerosis, increased platelet reactivity and activation of coagulation factors …

Cardiovascular disease remains the main cause of morbidity and mortality in patients with
diabetes. The risk of vascular ischemia is increased in this population and outcome …

Diabetes is associated with hypofibrinolysis by mechanisms that are only partially
understood. We investigated the effects of in vivo plasminogen glycation on fibrinolysis …

In the last few years, there has been increasing focus on the impact of interventions on
cardiovascular outcomes in patients with type 2 diabetes. Insulin resistance and …

Diabetes is associated with the development of premature cardiovascular disease (CVD),
which relates to the clustering of risk factors such as dyslipidaemia, hypertension, obesity …

Although the two phenomena are usually studied separately, we summarise a considerable
body of literature to the effect that a great many diseases involve (or are accompanied by) …

To obtain blood meals, haematophagous animals are armed with potent pharmacological
molecules to overcome several of their hosts' response systems. Among them, a large …

Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after
acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation …

Cardiovascular events occurring in type 2 diabetes (T2DM) are a major problem in clinical
practice. In particular, the risk of myocardial infarction (MI) presented by patients affected by …